MX2015009085A - Peptido. - Google Patents

Peptido.

Info

Publication number
MX2015009085A
MX2015009085A MX2015009085A MX2015009085A MX2015009085A MX 2015009085 A MX2015009085 A MX 2015009085A MX 2015009085 A MX2015009085 A MX 2015009085A MX 2015009085 A MX2015009085 A MX 2015009085A MX 2015009085 A MX2015009085 A MX 2015009085A
Authority
MX
Mexico
Prior art keywords
peptide
apitope
mog
myelin oligodendrocyte
oligodendrocyte glycoprotein
Prior art date
Application number
MX2015009085A
Other languages
English (en)
Other versions
MX369414B (es
Inventor
David Wraith
Original Assignee
Apitope Int Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apitope Int Nv filed Critical Apitope Int Nv
Publication of MX2015009085A publication Critical patent/MX2015009085A/es
Publication of MX369414B publication Critical patent/MX369414B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Abstract

Se provee un péptido el cual es capaz de unirse a una molécula del MHC in vitro y de ser presentado a una célula T sin procesamiento del antígeno (es decir, un apítope), cuyo péptido comprende una porción de la región 40 a 60 de la glucoproteína de oligodendrocitos de la mielina (MOG); en particular, se provee un epítope el cual se selecciona de los siguientes péptidos de la glucoproteína de oligodendrocitos de la mielina: MOG 41-55, 43-57, 44-58 y 45-59; se provee también el uso de dicho péptido en una composición farmacéutica y un método para tratar y/o prevenir una enfermedad usando dicho péptido.
MX2015009085A 2013-01-15 2014-01-13 Peptido. MX369414B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1300684.6A GB201300684D0 (en) 2013-01-15 2013-01-15 Peptide
PCT/IB2014/058233 WO2014111840A2 (en) 2013-01-15 2014-01-13 Peptide

Publications (2)

Publication Number Publication Date
MX2015009085A true MX2015009085A (es) 2016-02-16
MX369414B MX369414B (es) 2019-11-07

Family

ID=47757995

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009085A MX369414B (es) 2013-01-15 2014-01-13 Peptido.

Country Status (16)

Country Link
US (2) US9862751B2 (es)
EP (1) EP2945966B1 (es)
JP (1) JP6347065B2 (es)
KR (1) KR102169902B1 (es)
CN (1) CN105121463B (es)
AU (1) AU2014206592B2 (es)
BR (1) BR112015016780A2 (es)
CA (1) CA2897655C (es)
GB (1) GB201300684D0 (es)
HK (1) HK1211596A1 (es)
IL (1) IL239871B (es)
MX (1) MX369414B (es)
RU (1) RU2675479C2 (es)
SG (1) SG11201505526TA (es)
WO (1) WO2014111840A2 (es)
ZA (1) ZA201504987B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
CN106986930B (zh) * 2017-04-14 2021-06-11 广东省生物资源应用研究所 一种诱导食蟹猴实验性自身免疫性脑脊髓炎动物模型的蛋白和应用
JP7419229B2 (ja) * 2017-08-14 2024-01-22 百明信康生物技術（浙江）有限公司 方法
GB201909774D0 (en) 2019-07-08 2019-08-21 Apitope Tech Bristol Limited Method

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960705038A (ko) * 1993-09-03 1996-10-09 스테시 엘. 채닝 자기 면역 질환에 관련된 프로토콜에서 미엘린 올리고덴드로시트 당 단백질 및 그의 펩타이드 부분들의 용도(users of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune desease)
WO1995007096A1 (en) 1993-09-06 1995-03-16 La Trobe University Treatment of autoimmune disease
US6251396B1 (en) 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
WO1997035879A1 (en) * 1996-03-28 1997-10-02 Immulogic Pharmaceutical Corporation Myelin oligodendrocyte glycoprotein peptides and uses thereof
SE9703287D0 (sv) 1997-09-11 1997-09-11 Astra Ab Peptides
ES2338890T3 (es) 1999-03-12 2010-05-13 The Board Of Trustees Of The Leland Stanford Junior University Vacunacion por dna para el tratamiento de enfermedades autoinmunes.
IL132611A0 (en) 1999-10-27 2001-03-19 Yeda Res & Dev Synthetic genes and polypeptides and pharmaceutical compositions comprising them
DK1267909T3 (da) 2000-03-29 2010-11-08 Univ Ohio State Res Found Fremgangsmåder til blokering af vævsdestruktion ved autoreaktive T-celler
HU229377B1 (hu) 2000-08-21 2013-11-28 Apitope Technology Bristol Ltd Tolerogén humán peptidek
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
CA2614171C (en) 2001-10-03 2012-04-24 President And Fellows Of Harvard College Copolymers for suppression of autoimmune diseases, and methods of use
JP5010798B2 (ja) 2001-10-03 2012-08-29 プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 自己免疫疾患を抑制するためのコポリマー、及びその使用方法
IL146016A0 (en) 2001-10-17 2002-07-25 Yeda Res & Dev Synthetic peptides and dna sequences and compositions comprising them for treatment of multiple sclerosis
DK1456380T3 (da) 2001-11-02 2012-07-30 Giuliani Int Ltd SMAD7-inhibitorer til behandling af CNS-sygdomme
EP2363710B1 (en) 2002-08-08 2015-07-01 Baylor College Of Medicine Isolation and identification of T cells
CA2499843A1 (en) 2002-09-25 2004-04-08 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
JP2008500006A (ja) 2003-05-21 2008-01-10 バイオテック トゥールス ソシエテ アノニム ペプチド複合体
WO2005044982A2 (en) 2003-09-05 2005-05-19 Oregon Health & Science University Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells
AU2011202900B2 (en) 2003-09-05 2012-08-02 Oregon Health & Science University Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells
WO2006057003A2 (en) 2004-11-29 2006-06-01 Yeda Research And Development Co. Ltd. Induction of neurogenesis and stem cell therapy in combination with copolymer 1
AU2012201067A1 (en) 2005-03-14 2012-03-15 B.G. Negev Technologies And Applications Ltd. Compositions of HSP60 peptides and viral antigens for vaccination and diagnosis
IL185932A (en) 2005-03-14 2014-02-27 Yeda Res & Dev Viral antigens, conjugates and preparations containing them, for vaccination and diagnosis
EP1858548B1 (en) 2005-03-14 2012-06-20 Yeda Research And Development Co., Ltd. Compositions of hsp60 peptides and viral antigens for vaccination and diagnosis
US8202835B2 (en) 2005-06-17 2012-06-19 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
CN101267834B (zh) 2005-09-28 2013-06-05 赛托斯生物技术公司 白介素-1偶联物及其用途
WO2007055378A1 (ja) 2005-11-14 2007-05-18 Cell Signals Inc. 調節性ｔ細胞の機能異常に基づく疾患の治療方法及び予防方法
CA2629551A1 (en) 2005-11-17 2007-05-31 The Cleveland Clinic Foundation Multipotent neural stem cells
US7803364B2 (en) 2005-11-17 2010-09-28 The Cleveland Clinic Foundation Multipotent neural stem cells
EP1991259B1 (en) 2006-02-15 2012-10-10 Ramot at Tel-Aviv University Ltd. Viral display vehicles for treating multiple sclerosis
JP2009531295A (ja) 2006-02-22 2009-09-03 ユニバーシティ オブ チューリッヒ 自己免疫疾患又は脱髄疾患を処置するための方法
EP2420833B1 (en) 2006-05-05 2015-09-02 Opexa Therapeutics T-cell vaccine
AU2012202776A1 (en) 2006-05-31 2012-05-31 Lpath, Inc. Novel Bioactive Lipid Derivatives, Immune-derived Moieties Reactive Thereto, and Methods of Making and Using Same
AU2012202713B2 (en) 2006-05-31 2015-04-09 Lpath, Inc. Immune-derived moieties reactive against lysophosphatidic acid
US8148084B2 (en) 2006-06-22 2012-04-03 Dana-Farber Cancer Institute, Inc. Diagnosis of autoimmune disease
AU2007308838B2 (en) 2006-10-25 2014-03-13 Revalesio Corporation Mixing device and output fluids of same
KR101581279B1 (ko) 2006-10-27 2015-12-31 엘파스, 인크. 스핑고신-1-포스페이트 결합을 위한 조성물 및 방법
US8188218B2 (en) 2006-10-27 2012-05-29 University Of Kansas Bi-functional peptides for multiple sclerosis treatment and diagnosis
ES2456963T3 (es) 2007-06-04 2014-04-24 Rappaport Family Institute For Research In The Medical Sciences Agentes para el tratamiento de enfermedades inflamatorias y métodos para usar los mismos
EP2050814A1 (en) 2007-10-17 2009-04-22 Txcell Compositions for treating multiple sclerosis
US20090227018A1 (en) 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
DK2211892T3 (da) * 2007-10-31 2011-10-31 Apitope Technology Bristol Ltd Sammensætninger omfattende myelinbasiske proteinpeptider og medicinske anvendelser deraf
US20110111395A1 (en) 2008-02-14 2011-05-12 Jean-Marie Saint-Remy Cd4+cells with cytolytic properties
JP2012505257A (ja) 2008-10-13 2012-03-01 バイオヴィスタ，インコーポレイテッド 多発性硬化症治療のための組成物および方法
AU2009308362B2 (en) 2008-10-22 2016-02-04 Revalesio Corporation Compositions and methods for treating thymic stromal lymphopoietin (TSLP)-mediated conditions
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
WO2010055510A2 (en) 2008-11-12 2010-05-20 Yeda Research And Development Co. Ltd. Diagnosis of multiple sclerosis
EP2233502A1 (en) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
CA2758738A1 (en) 2009-04-27 2010-11-04 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
US8703711B2 (en) 2009-06-09 2014-04-22 Val-Chum, Limited Partnership Ninjurin-1 modulation and uses thereof
US8293468B2 (en) 2009-06-10 2012-10-23 Centre Hospitalier De L'université De Montréal MCAM modulation and uses thereof
CN102666581A (zh) 2009-08-31 2012-09-12 艾普利穆恩公司 用于抑制移植物排斥的方法和组合物
CN102811739A (zh) 2009-12-09 2012-12-05 田边三菱制药株式会社 T细胞活化抑制剂、含有其的药物组合物以及抑制t细胞活化的物质的筛选方法
WO2011097527A2 (en) 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
US20110189178A1 (en) 2010-02-04 2011-08-04 Xencor, Inc. Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
PL217128B1 (pl) 2010-08-02 2014-06-30 Inst Biochemii I Biofizyki Polskiej Akademii Nauk Syntetyczne geny kodujące fragmenty peptydowe naturalnych białek mielinowych przeznaczone do wywoływania efektu tolerancji pokarmowej, fragmenty DNA zawierające te geny, sposób otrzymywania tych peptydów w układzie mikrobiologicznym (bakteryjnym) oraz ich zastosowanie medyczne
EP2600878A4 (en) 2010-08-04 2014-06-11 Univ Duke REGULATORY B-CELLS AND ITS USES
WO2012017439A2 (en) 2010-08-04 2012-02-09 Ramot At Tel-Aviv University Ltd. Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases
AU2011289172B2 (en) 2010-08-12 2015-09-24 Revalesio Corporation Compositions and methods for treatment of taupathy
KR20130107293A (ko) 2010-09-03 2013-10-01 오레곤 헬스 앤드 사이언스 유니버시티 공유 결합된 펩티드를 갖는 재조합 ｔ 세포 수용체 리간드
US20130236473A1 (en) 2010-09-16 2013-09-12 Osaka University Therapeutic agents and prophylactic agents for symptoms accompanying autoimmune diseases, inflammatory diseases, allergy diseases and organ transplants
WO2012041867A2 (en) 2010-09-27 2012-04-05 China Agricultural University Combined antigen and dna vaccine for preventing and treating autoimmune diseases
WO2012045324A1 (en) 2010-10-07 2012-04-12 Mediagnost Gesellschaft Fur Forschung Und Herstellung Von Diagnostika Gmbh Method for detecting a parkinson's disease and test system
BR112013010213A2 (pt) 2010-10-26 2019-09-24 Technion Research & Development Foundation Ltd anticorpos que unem ligantes solúveis de receptores de célula t
WO2012092485A1 (en) 2010-12-31 2012-07-05 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules
EP2667888A4 (en) 2011-01-28 2015-11-11 Univ Oregon Health & Science LIGMPHES OF RECOMBINANT T LYMPHOCYTES AND ANTIBODIES BINDING TO LYMPHOCYTES B FOR THE TREATMENT OF AUTOIMMUNE DISEASES
US8685404B2 (en) * 2011-01-31 2014-04-01 Oregon Health & Science University Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction
SI2796132T1 (sl) 2011-03-01 2018-09-28 Pharnext Terapija nevroloških motenj, ki temelji na baklofenu in akamprozatu
JP5878447B2 (ja) 2012-09-12 2016-03-08 富士フイルム株式会社 ベースメイク化粧料
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide

Also Published As

Publication number Publication date
CA2897655A1 (en) 2014-07-24
GB201300684D0 (en) 2013-02-27
KR20150105365A (ko) 2015-09-16
US20150353616A1 (en) 2015-12-10
EP2945966B1 (en) 2019-07-03
BR112015016780A2 (pt) 2017-08-15
WO2014111840A2 (en) 2014-07-24
ZA201504987B (en) 2017-11-29
MX369414B (es) 2019-11-07
HK1211596A1 (en) 2016-05-27
US20180086802A1 (en) 2018-03-29
AU2014206592B2 (en) 2018-01-04
EP2945966A2 (en) 2015-11-25
US9862751B2 (en) 2018-01-09
US10377800B2 (en) 2019-08-13
RU2015134356A (ru) 2017-02-22
WO2014111840A3 (en) 2014-10-30
IL239871B (en) 2018-12-31
SG11201505526TA (en) 2015-08-28
AU2014206592A1 (en) 2015-07-23
IL239871A0 (en) 2015-08-31
CN105121463B (zh) 2020-11-27
KR102169902B1 (ko) 2020-10-26
CA2897655C (en) 2023-04-04
JP6347065B2 (ja) 2018-06-27
CN105121463A (zh) 2015-12-02
JP2016505008A (ja) 2016-02-18
RU2675479C2 (ru) 2018-12-19

Similar Documents

Publication Publication Date Title
PH12018502429A1 (en) Antibody molecules for cancer treatment
AU2017296095B2 (en) Multispecific antibodies against CD40 and CD137
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
TW201613962A (en) Fabs-in-tandem immunoglobulin and uses thereof
EA201590388A1 (ru) Способы лечения таупатии
MX2013010376A (es) Formulaciones estables para inyeccion parenteral de farmacos de peptido.
NZ707086A (en) Anti-cd40 antibodies and methods of use
MX359449B (es) Conjugados de anticuerpo fármaco anti-cd70.
NZ631701A (en) Apoptosis-including agents for the treatment of cancer and immune and autoimmune diseases
NZ715201A (en) Afucosylated anti-fgfr2iiib antibodies
MA40513A (fr) Conjugués médicament-anticorps anti-cdh6
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
MX2023000204A (es) Variantes de proteinas de union al factor h y metodos de uso de estas.
MX2012013875A (es) Anticuerpos de union sparc en sangre periferica y usos de los mismos.
EA201691020A1 (ru) Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина"
EA201791225A1 (ru) Композиции и способы применения солабегрона с модифицированным высвобождением при симптомах нижних мочевых путей
MX2016016419A (es) Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino.
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
MX369414B (es) Peptido.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
AU2012280776B2 (en) Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.

Legal Events

Date Code Title Description
FG Grant or registration